Global Strategic Fund, L.P.... Net Worth

The estimated Net Worth of Global Strategic Fund, L.P.... is at least $525 Tisíc dollars as of 1 April 2019. Global P owns over 50,000 units of Precision BioSciences stock worth over $525,000 and over the last 6 years Global sold DTIL stock worth over $0.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Global P DTIL stock SEC Form 4 insiders trading

Global has made over 1 trades of the Precision BioSciences stock since 2019, according to the Form 4 filled with the SEC. Most recently Global bought 50,000 units of DTIL stock worth $800,000 on 1 April 2019.

The largest trade Global's ever made was buying 50,000 units of Precision BioSciences stock on 1 April 2019 worth over $800,000. On average, Global trades about 50,000 units every 0 days since 2019. As of 1 April 2019 Global still owns at least 50,000 units of Precision BioSciences stock.

You can see the complete history of Global P stock trades at the bottom of the page.

Insiders trading at Precision BioSciences

Over the last 6 years, insiders at Precision BioSciences have traded over $352,500 worth of Precision BioSciences stock and bought 224,670 units worth $1,909,002 . The most active insiders traders include Raymond F Schinazi, Llc Fmr a Michael Amoroso. On average, Precision BioSciences executives and independent directors trade stock every 22 days with the average trade being worth of $357,735. The most recent stock trade was executed by Dario Scimeca on 7 June 2024, trading 301 units of DTIL stock currently worth $3,161.

What does Precision BioSciences do?

Precision BioSciences, Inc., a clinical stage gene editing company, develops vivo gene editing and ex vivo allogeneic CAR T therapies in the United States. The company operates through two segments, Therapeutic and Food. It offers ARCUS, a genome editing platform to cure genetic disorders. The company also provides Ex vivo Allogeneic CAR T Immunotherapy, a form of immunotherapy in which a specific type of immune cell, called a T cell, is genetically engineered to recognize and kill cancer cells; PBCAR0191, which is in Phase 1/2a clinical trial in adult patients with R/R NHL or R/R B-cell precursor acute lymphoblastic leukemia, or B-ALL; PBCAR19B, an anti-CD19 CAR T candidate built on the stealth cell platform utilizing a single-step gene edit to minimize the risk of chromosome abnormalities; and PBCAR269A, an investigational allogeneic CAR T immunotherapy targeting BCMA for the treatment of R/R multiple myeloma. The company has development and commercial license agreement with Servier to develop allogeneic chimeric antigen receptor T cell therapies for antigen targets, hematological cancer targets beyond CD19, and solid tumor targets; Tiziana Life Sciences to evaluate foralumab, a fully human anti-CD3 monoclonal antibody as a lymphodepleting agent for the potential treatment of cancers; and iECURE, Inc. to develop ARCUS-based gene editing therapies. Precision BioSciences, Inc. was incorporated in 2006 and is headquartered in Durham, North Carolina.

Complete history of Global P stock trades at Precision BioSciences

Precision BioSciences executives and stock owners

Precision BioSciences executives and other stock owners filed with the SEC include:

• Michael Amoroso,
  Pres, CEO & Director
• Matthew R. Kane,
  Advisor
• Dr. Christopher R. Heery,
  Consultant
• Dora Alvarado,
  Sr. VP of Human Resource
• Maurissa Messier,
  Sr. Director of Corp. Communications
• Heather King,
  Director of Marketing Communications & PR
• Bruce Stevens,
  VP of Quality & Compliance
• Dr. Derek Jantz Ph.D.,
  Co-Founder, Chief Scientific Officer & Director
• Shane Barton,
  VP, Corp. Controller & Principal Accounting Officer
• Dr. David S. Thomson Ph.D.,
  Chief Operating Officer
• John Alexander Kelly,
  Chief Financial Officer
• Dr. Jefferson J. Smith Ph.D.,
  Co-Founder & CTO
• Dario Scimeca,
  Gen. Counsel & Sec.
• Shari Lisa Pire,
  
• Samuel C. Wadsworth,
  
• Stanley Frankel,
  
• Kevin Buehler,
  
• Shane Barton,
  VP & Corporate Controller
• Fayaz Khazi,
  CEO of Elo Life Systems
• Raymond F Schinazi,
  Director
• Matthew R. Kane,
  President and CEO
• Abid Ansari,
  Chief Financial Officer
• Christopher Heery,
  Chief Medical Officer
• Shalini Sharp,
  Director
• Geno J Germano,
  
• Tony Dung Ling Yao,
  Director
• Llc Fmr,
  
• Derek Jantz,
  Chief Scientific Officer
• Global Strategic Fund, L.P....,
  
• David S. Thomson,
  Chief Operating Officer
• Michael Amoroso,
  President and CEO
• Melinda Brown,
  
• J. Jefferson Smith,
  Chief Research Officer
• Dario Scimeca,
  General Counsel and Secretary
• John Alexander Kelly,
  Chief Financial Officer
• Alan List,
  Chief Medical Officer